# Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients

> **NCT07162090** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Sarcopenia
- Anemia Associated With Chronic Kidney Disease (CKD)
- Dialysis Patients

## Interventions

- **DRUG:** Roxadustat
- **DRUG:** Recombinant human erythropoietin (EPO)

## Key facts

- **NCT ID:** NCT07162090
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-10
- **Primary completion:** 2026-09-10
- **Final completion:** 2026-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07162090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07162090, "Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07162090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*